MedaSystems Strengthens Executive Team with Appointment of Anton White as Vice President of Growth

MENLO PARK, Calif.--(BUSINESS WIRE)--MedaSystems, the leading SaaS platform for Expanded Access (EA) and Investigator‑Initiated Studies (IIS), today announced that healthcare‑technology veteran Anton White has joined the company as Vice President of Growth. White will lead global go‑to‑market strategy and execution as MedaSystems scales to meet accelerating demand from biopharmaceutical partners worldwide.

“Anton brings a rare combination of deep life‑sciences expertise and a growth‑mindset leadership style that aligns perfectly with our culture,” said Brian Irwin, Chief Executive Officer of MedaSystems. “His track record of building high‑performing, customer‑centric teams will be instrumental at this pivotal moment as we enter our next phase of rapid expansion.”

White joins MedaSystems after more than two decades of success driving revenue and building award‑winning teams at Optum Life Sciences, Eli Lilly, Celgene, and OptumRx. At Optum, he oversaw national sales and strategic partnerships, delivering data, analytics, and clinical‑services solutions to top‑10 global pharma companies and emerging biotech companies.

“I’m thrilled to join MedaSystems and help transform the way BioPharma and physicians collaborate to provide compliant, compassionate access to investigational therapies,” said Anton White, Vice President of Growth, MedaSystems. “Together we’ll empower sponsors and investigators with software that streamlines regulatory processes and accelerates patient access to life‑changing treatments.”

White holds an MBA in Pharmaceutical & Healthcare Marketing from Saint Joseph’s University, a BA in Management and Spanish from Gettysburg College, and a Sales Team Management Strategies certificate from Columbia Business School Executive Education.

About MedaSystems

MedaSystems is the leading developer of secure, GxP‑compliant software for managing requests for experimental therapies—including Expanded Access, Post‑Trial Access, and Investigator‑Initiated Studies. By connecting physicians and pharmaceutical companies in a centralized, audit‑ready environment, MedaSystems reduces administrative burden, improves data quality, and helps patients worldwide gain timely access to investigational treatments.